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508topenia, and acute renal failure. The atypical form of HUS is a disease characterized by complement
overactivation. Inherited defects in complement genes and acquired autoantibodies against complement
regulatory proteins have been described. Incomplete penetrance of mutations in all predisposing genes is
reported, suggesting that a precipitating event or trigger is required to unmask the complement regulatory
deficiency. The underlying genetic defect predicts the prognosis both in native kidneys and after renal
transplantation. The successful trials of the complement inhibitor eculizumab in the treatment of atypical HUS
will revolutionize disease management.
Semin Nephrol 33:508-530 C 2013 Elsevier Inc. All rights reserved.
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protein, thrombomodulin, transplantationThe hemolytic uremic syndrome (HUS) is char-acterized by the triad of thrombocytopenia,microangiopathic hemolytic anemia, and acute
renal failure.1 The most common form of HUS is
secondary to shiga toxin (Stx)-producing bacteria,
typically Escherichia coli O157:H7. Atypical HUS
(aHUS) has been used to classify any HUS not caused
by Stx. A variety of precipitating events have been
associated with aHUS including infections, drugs,
autoimmune conditions, transplants, pregnancy, and
metabolic conditions (Table 1). These have frequently
been called secondary aHUS. With the discovery of
the role of complement gene mutations in aHUS,
primary aHUS has been used to refer to those cases
with documented complement dysregulation.
Although a useful aide memoir, these terms do not
account for the increasing recognition that patients
with an underlying complement risk factor often
require a secondary trigger for aHUS to manifest.
Classifications that take account of both the genetic
background and etiologic trigger are beginning to be
introduced.2 The best estimate of aHUS incidence issee front matter
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Se2 of 106 in a North American population,3 although
the precise proportion with an underlying complement
defect is not known.PATHOLOGY
In acute aHUS, the pathologic picture is of capillary
thrombosis. Glomerular capillary wall thickening is
seen as a result of endothelial cell swelling and
accumulation of flocculent material between the endo-
thelial cell and the basement membrane. Platelet and
fibrin thrombi result in occlusion of the glomerular
capillaries. Fibrinoid necrosis of the afferent arteriole
associated with thrombosis also may be seen. Mesan-
giolysis occurs early in the disease process and sub-
sequently is replaced by sclerotic changes. Early arterial
changes are variable, ranging from only mild endothelial
swelling to fibrinoid necrosis with occlusive thrombus
formation. Subsequently, there is mucoid intimal hyper-
plasia with narrowing of the vessel lumen. Deposition of
fibrin or fibrinogen in the glomeruli and in the mesan-
gium, as well as within the vessel walls, are seen on
immunofluorescence. Complement and immunoglobulin
deposits along the capillary loops of glomeruli may be
seen.4THE COMPLEMENT SYSTEM
The complement system is an ancient defense mecha-
nism that stimulates the inflammatory response and
destroys pathogens through opsonization and lysis5
(Fig. 1). In addition to protecting the host against
invading pathogens, it bridges innate and adaptive
immunity and it disposes of immune complexes and
injured tissues and cells.6
The alternative pathway of complement (AP), which
plays a key role in the pathogenesis of aHUS, is
continually activated by a tick-over mechanism, and
can also be triggered by the classic and lectin pathways.minars in Nephrology, Vol 33, No 6, November 2013, pp 508–530
Table 1. Triggers of aHUS
Trigger Reference
Non-Stx toxin diarrheal illnesses 51,94,95
Norovirus 161,162
Campylobacter upsaliensis 163
Clostridium difficile 164
Respiratory infections 51
Bordetella pertussis infection 10,165
Streptococcus pneumonia 166
Haemophilus influenzae 10
Other bacterial
Fusobacterium necrophorum 167
Viral illnesses
Varicella 168
Cytomegalovirus 169
Influenza H1N1 170
Hepatitis A 171
Hepatitis C 172
Human immunodeficiency virus 173
Coxsackie B virus 174
Epstein–Barr virus 175
Dengue 176
HHV6 177
Human parvovirus B19 178
Parasites
Plasmodium falciparum 179
Pregnancy 51,98,180
Drugs
Cisplatin 181
Gemcitabine 182
Mitomycin 183
Clopidogrel 184
Quinine 185,186
Interferon-alfa, -beta 187,188
Anti–vascular endothelial growth factor 189
Campath 190
Cyclosporin tacrolimus 191
Ciprofloxacin 192
Oral contraceptives 193–195
Illicit drugs (eg, cocaine, heroin, ecstasy) 196
Autoimmune
Anticardiolipin 197
C3Nef 198
Systemic lupus erythematosus 199
Vaccination
Hepatitis B 10
Bone marrow transplantation 200
Malignancy (gastric, breast, prostate, lung, colon,
ovarian, pancreatic, lymphoma)
201
Combined methylmalonic aciduria and
homocystinuria
202
Atypical HUS 509In the AP, complement C3 undergoes spontaneous
hydrolysis, depositing C3b onto the surface of foreign
and host cells in the vicinity. On an activating surface
such as a bacterium, C3b joins with factor B, which
then is cleaved by factor D to form the C3 convertase,
C3bBb. The binding of properdin stabilizes this
enzyme. This enzyme complex then cleaves more C3
to C3b to initiate a feedback loop. Downstream of thisamplification loop, C3b also may join with the C3
convertase to form the C5 convertase. C5 is cleaved to
the anaphylatoxin C5a and C5b, which initiates for-
mation of the lytic membrane attack complex (C5b–9)
(Fig. 1). To protect host cells from collateral comple-
ment damage, many soluble and membrane-associated
complement regulatory proteins function to inactivate
complement on their surface. It is the imbalance
between complement activation and regulation on host
cell surfaces that underlies the pathogenesis of aHUS.
COMPLEMENT FACTOR H
Mutations in complement factor H (CFH) account for
approximately 25% of the genetic predisposition to aHUS
(Table 2).7–15 CFH is the most important fluid-phase
regulator of the AP of complement.16 CFH is composed
of 20 complement control protein modules (CCPs)17
(Fig. 2). The four N-terminal CCPs (CCPs 1-4) mediate
the complement regulatory functions of the protein by the
following: (1) acting as a cofactor for factor I–mediated
proteolytic inactivation of C3b, (2) competing with factor
B for C3b binding, and (3) accelerating the decay of the
C3 convertase into its components.
In addition to regulating complement in the fluid
phase, CFH also can protect host surfaces by binding to
polyanions such as the glycosaminoglycans.18 CFH has
two glycosaminoglycan binding domains in CCPs 6 to
8 and CCPs 19 and 20,17 which have different sulfate
specificities resulting in the C-terminal domains (CCP 19
and 20) being predominantly responsible for binding to
kidney, and CCPs 6 to 8 being responsible for binding in
the eye.19 Other recent studies have shown that CFH also
binds to the lipid peroxidation product malondialde-
hyde,20 the acute phase proteins, C-reactive protein,21–23
and pentraxin 3,24 as well as necrotic cells.21
The majority of mutations in CFH are heterozygous,
are located in CCPs 19 and 20 (Fig. 2), and do not
usually result in a quantitative deficiency of CFH.
Structural and functional analysis of the C-terminal
mutants has revealed variable consequences on binding
to heparin, C3b, and endothelial cells; however, cell
surface complement regulation is consistently impaired
as measured using sheep erythrocyte lysis assays25–27
(Table 3). Thus, these C-terminal mutants are predicted
to fail to control complement activation at the glomer-
ular endothelium. In keeping with this, renal biopsy
data from an aHUS patient with a C-terminal mutant
showed reduced CFH binding to renal endothelium
compared with wild type.27 C-terminal CFH mutants
also have been shown to have impaired binding to
platelets resulting in increased complement activation
with consequent platelet activation, aggregation, and
release of tissue factor–expressing microparticles.28
Although CFH mutations cluster in the C-terminus,
genetic changes are reported throughout the molecule.
C3b
Bb
C3b
C3b
B
Inflammation
Anaphylatoxins (C3a, C5a)
Opsonization
(C3b)
Cell Lysis
Membrane Attack Complex (C5b-9)
CFH CFI
MCP
C3dg
αCFH Ab
Complement Activation Complement Regulation
αCFI Ab
Figure 1. Complement activation and regulation. The AP is a positive amplification loop. C3b interacts with factor
B (B), which then is cleaved by factor D to form the AP C3 convertase (C3bBb). This enzyme complex is attached
to the target covalently via C3b while Bb is the catalytic serine protease subunit. C3 is the substrate for this
convertase, thus creating a powerful feedback loop. Unchecked, this leads to activation of the terminal
complement pathway with generation of the effector molecules, the anaphylatoxin C5a, and the membrane
attack complex (C5b-9). To protect host cells from bystander damage the AP is down-regulated by complement
regulators including CFH, CFI, and MCP. Activating mutations in C3 and CFB and loss-of-function mutations in
CFH, CFI, and MCP, in addition to autoantibodies to CFH and CFI, result in overactivation of the AP with
resultant aHUS.
D. Kavanagh, T.H. Goodship, and A. Richards510Mutations in the N-terminal region of CFH (CCP 1-4)
have been reported and functional analysis has shown that
they are defective in their ability to control the AP both in
the fluid phase and on cell surfaces.29 Sequence variants
also have been described in the intervening CCPs of
CFH, although for many of these changes the functional
consequences and importance in pathogenesis remains
uncertain. Tortajada et al30 examined two of these
variants of uncertain significance (VUS) and showed no
functional consequences. They went on to show that these
variants form part of an infrequent ancient CFH haplo-
type in Caucasians that is not enriched in the aHUS
population, highlighting the importance of modeling
genetic mutations before ascribing functional significance.
CFH resides in the Regulators of Complement
Activation (RCA) cluster and the architecture of this
region makes it particularly prone to genomic rear-
rangements. The gene for CFH is in close proximity to
the genes encoding the five factor H–related proteins
that are thought to have arisen from several large
genomic duplications and thus have a very high degree
of sequence identity to CFH.
This homology predisposes to gene conversions and
genomic rearrangements through nonallelic homologous
recombination and microhomology-mediated end joining.
The CFH mutations S1191L, V1197A, and combined
S1191L/V1197A arose through gene conversion between
CFHR1 and CFH.31 A hybrid (fusion) gene comprising
the 21 N-terminal exons of CFH and the 2 C-terminalexons of CFHR1 was shown to have arisen through
nonallelic homologous recombination and resulted in
aHUS.32 More recently, a hybrid gene consisting of the
22 N-terminal exons of CFH and the 5 C-terminal
domains of CFHR3 arising through microhomology-
mediated end joining was reported in aHUS.33 As with
C-terminal point mutations in CFH, these hybrid genes
also result in loss of cell-surface complement regulation.
A transgenic mouse lacking the C-terminal domains of
CFH (Cfh-/-Δ16–20) was generated to provide an in vivo
model of aHUS.34 These mice spontaneously developed
aHUS, confirming the importance of local endothelial cell
complement regulation35 in vivo. Goicoechea de Jorge
et al36 also have crossed the Cfh-/-Δ16–20 mouse with a
C5-deficient mouse to investigate the role of C5 activa-
tion in the pathogenesis of aHUS. These C5-/-
CFH-/-Δ16–20 mice do not develop aHUS, suggesting
a critical role downstream of C3b generation in aHUS.COMPLEMENT FACTOR I
Mutations in complement factor I (CFI) account for
between 5% and 10% of aHUS (Tables 2 and 4).11,37–44
CFI is a serum serine protease that functions as a
critical mediator of complement regulation by cleaving
C3b and C4b in the presence of its cofactors (CFH for
C3b; C4b binding protein for C4b; membrane cofactor
protein [MCP] and complement receptor 1 for both). It
is synthesized predominantly by the liver. The CFI
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Atypical HUS 511mutations described in aHUS are all heterozygous.
These mutations cluster in the serine protease domain
(Fig. 3 and Table 4).
Functional analysis has been performed for a num-
ber of mutants and shows a loss of both alternative and
classic pathway regulatory activity in the fluid phase
and on cell surfaces (Table 4).39,41,42 As seen in CFH,
several VUS have been described in CFI in which
analysis has failed to show any alteration in secretion
or function (eg, G261D). Such variants may not be
involved in the pathogenesis of disease.
MEMBRANE COFACTOR PROTEIN
Mutations in MCP (CD46) are found in approximately
10% of patients with aHUS11,40,43–47 (Table 2). MCP is
a surface-bound complement regulatory protein that
acts as a cofactor for the CFI-mediated cleavage of C3b
and C4b that are deposited on host cells.48
The majority of mutations described in aHUS are
found in the extracellular four CCP domains that are
responsible for C3b and C4b binding (Table 5 and
Fig. 4). Most MCP mutations described to date have
resulted in a quantitative defect in MCP (75%). The
remaining mutations have been shown to result in a
secreted, nonfunctional protein (Table 5).
ACTIVATING MUTATIONS IN COMPLEMENT
COMPONENTS
Mutations have been described more recently in the
complement components C3 and complement factor B
(CFB). C3 is cleaved to form the anaphylatoxins C3a
and C3b, which are highly reactive, and can bind to
cell surfaces via their reactive thioester. C3b then can
interact with CFB in the presence of factor D to form
the AP C3 convertase (C3bBb), which cleaves further
C3, introducing a positive-feedback loop.
Mutations in C3 have been reported in several
cohorts of aHUS patients9–11,49–54 at a frequency of
2% to 10% (Table 2). Initial functional analysis
showed that MCP was unable to bind to mutant C3,
preventing its cleavage to iC3b.50 Two C3 mutations
have been described that resulted in decreased secre-
tion and their role in pathogenesis remains uncertain.
More recently, two mutations in C3 have been reported
that bind to CFB with higher affinity, resulting in
increased C3 convertase formation.52,55 These muta-
tions result in increased complement activation on
platelets52 and glomerular endothelium55 (Fig. 5 and
Table 6).
Gain-of-function mutations also have been reported
in CFB although these appear to be rare.9,10,51,56–58
Goicoechea de Jorge et al56 described two mechanisms
through which these separate mutations led to increased
complement activation. One mutant (F286L) showed
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Figure 2. CFH and aHUS-associated mutations. CFH is composed of 20 CCP modules. The N-terminal modules
(CCP1-4) bind to C3b and act as a cofactor for the CFI-mediated cleavage to the inactive iC3b. The C-terminal
modules (CCP19 and 20) bind to C3b and glycosaminoglycans on host cells to mediate cell surface protection.
Genetic variants described in aHUS cluster in CCPs 19 and 20, but can be seen throughout the molecule.
Functional analysis of aHUS-associated variants has focused predominantly on the C-terminal variants (Table 3).
D. Kavanagh, T.H. Goodship, and A. Richards512enhanced formation of the C3bB proenzyme that
resulted in a more active enzyme in vivo. The other
mutant (K323E) formed a C3bBb enzyme more resist-
ant to decay by the complement regulators decay
accelerating factor (CD55) and CFH. This also caused
increased enzyme activity.56 Subsequent analysis of
two further mutants located in the von Willebrand type
A domain (D279G and K350N) showed increased
convertase formation and resistance to CFH dissocia-
tion, ultimately resulting in increased complement
deposition on endothelial cells.55THROMBOMODULIN
Thrombomodulin (THBD) facilitates the activation of
protein C by thrombin59 and enhances thrombin-
mediated activation of plasma procarboxypeptidase B
(CPB2), an inhibitor of fibrinolysis that also inactivates
complement-derived anaphylatoxins C3a and C5a. It
has also been shown to down-regulate the AP by
accelerating CFI-mediated inactivation of C3b in the
presence of cofactors.60 Mutations in THBD recently
were described in aHUS. The variations reported were
heterozygous missense mutations, with no mutations
resulting in a loss of secretion. These mutationsresulted in a loss of cofactor activity.60 Maga et al11
also have reported THBD genetic variants in aHUS,
although they suggested that at least one of the
previously reported mutations was a polymorphism
present in 3% of the population and that several THBD
variants were present with an additional mutation. No
isolated THBD mutations were described in a large
French cohort of patients (n ¼ 214), although a few
individuals carried THBD genetic variants in addition
to a mutation in a known complement gene.49 Several
large cohorts of aHUS have yet to report on the
frequency of genetic variants in THBD in aHUS.OTHER GENETIC VARIANTS
Genetic screening of complement factor H–related
5 protein (CFHR5) in 3 separate cohorts of aHUS
patients was performed.11,61,62 Monteferrante et al62
did not detect any causative mutations in an Italian
cohort. Westra et al61 reported 3 VUS in CFHR5 in a
panel of 65 aHUS patients whereas Maga et al11
reported 3 VUS in aHUS (n ¼ 144) patients, 2 of
whom carried an additional known mutation. No
mutation was seen to segregate in a large pedigree
with the reported cases being sporadic. The current
Table 3. Structural and Functional Consequences of CFH Mutations in aHUS
Mutant CCP
Structural
Changes
C3b/d
Binding
Heparin
Binding
Cofactor
Activity
Decay
Acceleration
Activity
Endothelial
Cell Binding
Hemolysis
Assay Reference
R53H 1 Local 2 N/A ↓ ↓ N/A ↓* 29,85
R78G 1 ND ↓ N/A ↓ ↓ N/A ↓* 29
S890I 15 ND 2 ND 2 ND ND 2† 30
V1007L 17 ND 2 ND 2 ND ND 2† 30
D1119G 19 Local ↓‡ 2 N/A N/A 2§ ↓* 25,203,204
Y1142C 19 ND ND ND N/A N/A ND ↓† 26
W1157R 19 ND ↓ ↓ N/A N/A ND ND 205
E1172X 20 ND ↓ ↓ N/A N/A ND ND 206,207
R1182S 20 Local ↓ ↓ N/A N/A ND ↓†,|| 24,25,204,208 ¶
W1183R 20 Local ↑ ↑ N/A N/A ND ↓|| 25,204
W1183L 20 Local ↓ ↓‡ N/A N/A ↓‡,§,# ↓|| 24,25,203–205,209¶
T1184R 20 Local ↑‡ ↑ N/A N/A ↑§ ↓|| 25,203,204,210
L1189R 20 Local ↑ ↑ N/A N/A ↑§ ↓†,|| 25,203,204,208
L1189F 20 Local ↑ ↑ N/A N/A ND ↓†,|| 25,204,208
S1191W 20 ND ND ND N/A N/A ND ↓† 208
S1191L 20 Local ↑‡ 2 N/A N/A ND ↓†,|| 25,31,211
S1191L/
V1197A
20 Local ↑‡ 2 N/A N/A ND ↓†,|| 25,31,204,211
V1197A 20 ND ↓‡ ↓‡ N/A N/A ND ↓† 31,204,205,208,209,211
E1198K 20 ND ND ND N/A N/A ↓# ↓† 27
R1210C 20 Local ↓ ↓‡ N/A N/A ↓# ↓|| 25,204,205,207–209
R1215G 20 Local ↓ ↓ N/A N/A ↓# ↓|| 25,205,207
R1215Q 20 ND 2 ↓ N/A N/A 2§ ND 203,204
P1226S 20 ND ↓ ↓ N/A N/A ND ND 205
NOTE. The amino acid numbering refers to the translation start site.
Abbreviations: N/A, not applicable; ND, not done.
*Hemolysis assay using factor H–deficient serum reconstituted with recombinant CFH1-4 in decay acceleration activity (DAA) and
cofactor activity (CA) sheep lysis assays.29
†Patient serum was used on sheep erythrocytes.208
‡Indicates contradictory results.
§Endothelial cell binding relates to mGEnC-1203 binding.
||Recombinant proteins competed with full-length CFH on human erythrocytes.25
¶Additional experiments have shown R1182S and W1183L have reduced binding to pentraxin 3.24
#Endothelial cell binding relates to HUVEC27,206,207 binding.
Atypical HUS 513limited understanding of the functional role of CFHR5
further adds to the uncertainty of its role in aHUS
pathogenesis and replication studies are required.
A functionally significant mutation (Q433P) in the
membrane attack complex regulator, clusterin, has
been reported in a family with aHUS.63 The affected
individual also carried a functionally significant muta-
tion in MCP; therefore, it is unclear whether mutations
in clusterin are sufficient alone to cause aHUS.
FACTOR H AUTOANTIBODIES
In addition to the genetic abnormalities described in
aHUS, autoantibodies to CFH also have been linked
to disease in 4% to 14% of aHUS patients
(Table 7).10,51,64–68 In a pediatric-only cohort, this
figure was reported to be as high at 25%.69
CFH autoantibodies in aHUS are strongly asso-
ciated with an 80-kb–long genomic homozygousdeletion of CFHR1 and CFHR3.10,65,66,70 More recent
analysis also has shown that some aHUS patients with
CFHR1 deficiency resulting from point mutations in
CFHR171 or from a deletion incorporating CFHR1
and CFHR471,72 have developed anti-CFH antibody
(Ab). This may suggest that deficiency of CFHR1 is
the predominant predisposing factor in the develop-
ment of autoantibodies. Despite this, deficiency of
CFHR1 is not a prerequisite for formation of autoanti-
bodies because several aHUS patients have been
reported with high titers of Ab with no evidence of
deficiency of CFHR1 or CFHR3.10,67,73,74 In many
cases, aHUS patients with anti-CFH Ab also carried
functionally significant mutations in other comple-
ment genes.67
The anti-CFH antibodies reported to date have been
predominantly of the IgG class, although a few IgA
anti-CFH Ab have been described.74 Mapping of the
epitopes initially suggested that the anti-CFH Ab
Table 4. Mutations in CFI Reported in aHUS and Functional Consequences
Mutation Domain
Serum CFI
Level
Recombinant
Secretion
Fluid Phase C3
Cofactor Activity
Fluid Phase C4
Cofactor Activity
Cell Surface
Activity Reference
C43F FIMAC ↓ ↓ N/A N/A N/A 41,49,93
P50A FIMAC ↓ ↓* ↓† ↓‡ ↓ 41,49,93
P64L FIMAC N/D N/D N/D N/D N/D 11
T72S FIMAC N/D N/D N/D N/D N/D 51
H118R CD5 2 N/D N/D N/D N/D 49,93
G119R CD5 2 N/D N/D N/D N/D 11,49,93
M138I CD5 2 2 2 2 N/D 39
M138V CD5 2 ↓ 2 2 ↑ 41,93
W145X CD5 ↓ ↓ N/A N/A N/A 38,41
N151S CD5 ↓ ↓ N/A N/A N/A 41,49,93
V152M CD5 N/D N/D N/D N/D N/D 43
G162D CD5 ↓ N/A N/A N/A N/A 44,147
N177I CD5 N/D N/D N/D N/D N/D 46
H183R CD5 2 2 2 2 2 11,41,49,212
A240G LDLr1 2 ↓ 2 2 ↓ 40,41,51
C247G LDLr1 N/D N/D N/D N/D N/D 46
C249G LDLr1 ↓ N/D N/A N/A N/A 92
G261D LDLr2 2 2 2 2 2 39,42,49,51
G287R LDLr2 N/D N/D N/D N/D N/D 11
c.784delA LDLr2 ↓ ↓ N/A N/A N/A 93
c.893delC LDLr2 ↓ ↓ N/A N/A N/A 38,41
I306S LDLr2 2 N/D N/D N/D N/D 49
R317W SP link 2 ↓ ↓* ↓* 2 39-41,51
I340T SP link 2 2 ↓ ↓ N/D 39,213
G342E SP 2 N/D N/D N/D N/D 49
I344V SP 2 N/D N/D N/D N/D 49
G349R SP N/D N/D N/D N/D N/D 51
I357M SP 2 N/D N/D N/D N/D 49,51
Y369S SP N/D N/D N/D N/D N/D 214
W399R SP N/D N/D N/D N/D N/D 51
D403N SP 2 N/D N/D N/D N/D 49,93
R406C SP 2 N/D N/D N/D N/D 67
I416L SP ↓ ↓ N/A N/A N/A 49,93,94
G424D SP 2 N/D N/D N/D N/D 93
A431T SP ↓ ↓ N/A N/A N/A 49,93
I433T SP 2 N/D N/D N/D N/D 93,94
K441R SP 2 N/D N/D N/D N/D 215
W456L SP ↓ ↓ N/A N/A N/A 49,93
Y459S SP 2 N/D N/D N/D N/D 37,49
R474X SP ↓ ↓ N/A N/A N/A 37,41,43,49
c.1446-
1450del
TTCAC
SP 2 ↓ N/A N/A N/A 39–41
D519N SP N/D 2 ↓ ↓ ↓ 39-41
K522T SP N/D N/D N/D N/D N/D 11
D524V SP 2 2 ↓* ↓* ↓ 37,39,49,93
c.1610ins AT SP ↓ ↓ N/A N/A N/A 41,80
W546X SP ↓ ↓ N/A N/A N/A 37,41
E554V SP N/D N/D N/D N/D N/D 51
P553S SP 2 N/D N/D N/D N/D 49,93
NOTE. The amino acid numbering refers to the translation start site. The previously reported rare genetic variant IVS12þ5G4T
was not included because it is not enriched in an aHUS population.
Abbreviations: N/A, not applicable; ND, not done; FIMAC, factor-I membrane attack complex domain; LDLr, low-density lipoprotein
receptor domains; SP, serine protease domain.
*Contradictory result.
†Only seen using CFH as a cofactor.
‡Only seen using C4b binding protein.
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C43FP50AP64LT72SR317W Y369S I416L I433TW456L
I357M
R406C
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M120I/V
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D524V
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I340T
G119R N151SV152M A240G Y459S
W546X
H118R W145X G162D C247G G287R G349R P553SE554V
Figure 3. Location of aHUS-associated mutations within the crystal structure of factor I (protein database
identification code: 2XRC).160 Factor I is a heterodimer consisting of a noncatalytic heavy chain linked by a
disulfide bond to a catalytic light chain. The domain structure of CFI is shown with the heavy chain comprising the
FIMAC domain, light blue; SRCR domain, pale green; LDLr1, cyan; and LDLr2, magenta; and the light chain or
serine protease domain, deep olive. aHUS-associated genetic variants are shown as red spheres. Yellow spheres
mark the catalytic triad of the serine protease domain. Functional analysis of aHUS-associated CFI variants are
described in Table 4.
Atypical HUS 515bound predominantly to the C-terminus,66,67,75,76 how-
ever, recently it was reported that the response was
polyclonal to multiple epitopes throughout CFH.77
There was also cross-reactivity with CFHR167,74,77
and CFHR2,77 but it was not reported for CFHR3 or
CFHR4A.74
Several studies have shown various functional con-
sequences of anti-CFH Abs. The antibodies have been
shown to reduce binding to C3b75,77 and other C3
fragments.77 They perturb CFH-mediated cell surface
protection75,77 and in some individuals the autoanti-
bodies also impair cofactor activity77 or decay accel-
erating activity.76 In keeping with this, low C3 levels
frequently are seen in the autoimmune form (Table 7).
It also has been shown that CFH autoantibodies
form immune complexes in the serum,74,77 which may
explain the low CFH levels seen in 28% of the cases.77
In addition, these immune complexes correlated with
disease activity.77 In summary, these functional studies
suggest a pathogenic role for CFH autoantibodies
in aHUS.
FACTOR I AUTOANTIBODIES
Autoantibodies to CFI also have been described in
aHUS but are much rarer than anti-CFH Abs (0%-
2%).68,78 Unlike anti-CFH Abs they are not associated
with a deletion of CFHR1 and 3. Anti-CFI Abs were
seen to form immune complexes in serum, however,
functional analysis showed only a minor effect in fluidphase cofactor activity.78 The co-existence of func-
tionally significant mutants in the majority of patients,
added to the lack of correlation of anti-CFI Ab titer and
disease activity, raise the possibility that they are an
epiphenomenon rather than a direct cause of disease.
Large replication studies will be needed to confirm this
initial observation.
GENETIC SUSCEPTIBILITY FACTORS
A number of single-nucleotide polymorphisms (SNPs)
in CFH have been shown to be associated with aHUS
in several studies.34,64,79–82 A haplotype in CFH
(CFH-H3; tgtgt) composed of these SNPs increases
this risk of aHUS two- to four-fold.34,49 This haplotype
contains a SNP in the region of CFH responsible for
cofactor activity. Functional analysis has shown that
the risk variant, CFH-Val62, has a subtle decrease in
cofactor activity compared with the protective var-
iant,29,83,84 in keeping with the minor structural differ-
ences between these SNPs.85
A haplotype block in MCP (MCPggaac) compris-
ing 2 SNPs in the promoter region has been associated
with a two- to three-fold increased risk of
aHUS.49,80,81 Some of these studies have suggested
that this risk occurs exclusively in those patients
already carrying complement mutations.80,82 Reporter
gene assays have suggested that this haplotype
reduces transcriptional activity by 25%,80 however,
this did not correlate with MCP cell surface
Table 5. Mutations in MCP Reported in aHUS and Functional Consequences
Mutation Domain Expression
C3b
Binding
C3 Cofactor
Activity
C4b
Binding
C4b Cofactor
Activity Reference
IVS2þ1G4C 1 ↓ N/A N/A N/A N/A 48,80
IVS2þ2T4G 1 ↓ N/A N/A N/A N/A 11,43,44,47,48
IVS1-1G4C 1 ↓ N/A N/A N/A N/A 40,48
Y29X 1 N/D N/D N/D N/D N/D 46
C35X 1 ↓ N/A N/A N/A N/A 51
C35Y 1 ↓ N/A N/A N/A N/A 40,48,51
E36X 1 ↓ N/A N/A N/A N/A 49
P50T 1 N/D N/D N/D N/D N/D 51
R59X 1 ↓ N/A N/A N/A N/A 40,44,47,51
C64F 1 ↓ N/A N/A N/A N/A 168
K65DfsX73 1 N/D N/D N/D N/D N/D 46
IVS2-2A4G 2 ↓ N/A N/A N/A N/A 11,40,47,48,170
C99R 2 ↓ N/A N/A N/A N/A 40,48
R103W 2 2 2 2* 2 2 48,216
R103Q 2 N/D N/D N/D N/D N/D 46
G130V 2 N/D N/D N/D N/D N/D 46
G135VfsX13 2 N/D N/D N/D N/D N/D 44
P165S 3 ↓ N/A N/A N/A N/A 46,48,80
E179Q 3 ↑ 2 2 2 ↓ 47,48
Y189D 3 ↓ N/A N/A N/A N/A 9,11,47-49,51
D185N/Y189D 3 ↓ N/A N/A N/A N/A 47,48
I208Y 3 N/A N/A N/A N/A N/A 46
G196R 3 ↓ N/A N/A N/A N/A 48
G204R 3 N/D N/D N/D N/D N/D 46
C210F 3 ↓ N/A N/A N/A N/A 46,92
W216C 3 N/D N/D N/D N/D N/D 11
P231R 4 N/D N/D N/D N/D N/D 11
S240P 4 2 ↓ ↓ 2 2 45,48
F242C 4 2 ↓ ↓ ↓ ↓ 11,46,48,51
Y248X 4 ↓ N/A N/A N/A N/A 47,48
T267fs270x 4 ↓ N/A N/A N/A N/A 48,51,217
Del D271-Ser272 4 ↓ N/A N/A N/A N/A 43,45,63
858-872delþD277NþP278S 4 ↓ N/A N/A N/A N/A 40,48
C852-856del 4 ↓ N/A N/A N/A N/A 48,80
c.983-984delAT TM N/D N/A N/A N/A N/A 11
A353V TM 2 2* 2 2 2 40,48,216
IVS10þ2T4C TM ↓ N/A N/A N/A N/A 49,218
T381I CT N/D N/D N/D N/D N/D 46
NOTE. The amino acid numbering refers to the translation start site.
Abbreviations: CT, cytoplasmic tail; N/A, not applicable; N/D, not done; TM, transmembrane.
*Inability to control complement was detected on cell surface assays only.
D. Kavanagh, T.H. Goodship, and A. Richards516expression in vivo.80,86,87 Further experiments on
human umbilical vein endothelial cells (HUVECs)
with risk and protective MCP haplotypes showed equal
MCP expression whether in the resting state, after
cytokine treatment, or free heme treatment. Likewise,
no increase in complement deposition could be shown
on HUVECs bearing the MCP risk haplotype.87
A SNP in C4b binding protein (R240H) was
associated with aHUS in cohorts from the United
Kingdom and France. C4b binding protein is the
predominant classic pathway fluid phase regulator but
also has weak AP regulatory activity. Functional
analysis showed inefficient AP regulation comparedwith wild type.88 In a replication study in a Spanish
cohort this association could not be confirmed.89
A CFHR1 polymorphism (CFHR1*B) resulting
from a gene conversion between CFH and CFHR1 is
associated strongly with aHUS in the homozygous
state,64 an association replicated by Fremeaux-Bacchi
et al.49 It has been suggested that because the
CFHR1*B is identical to CFH in CCP18 that it may
compete with CFH at the glomerular endothelium, thus
impairing complement regulation.
In a study examining SNPs in 47 complement genes
in two separate cohorts, SNPs in CFHR2 and CFHR4
were also associated with aHUS. In this study there
CCP1
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Figure 4. Mutations in MCP associated with aHUS. MCP is a transmembrane glycoprotein. It consists of 4 CCPs.
Following the CCPs is an alternatively spliced region, rich in serine, threonine, and proline (STP region). The STP
region is followed by a group of 12 amino acids of unknown function, a hydrophobic domain, a charged
transmembrane anchor, and the alternatively spliced cytoplasmic tail (CT). Mutations associated with aHUS are
clustered in the four extracellular CCPs of the molecule. Functional analysis of aHUS-associatedMCP variants are
described in Table 5.
Atypical HUS 517were no reproducible associations between SNPs and
aHUS outside the RCA cluster.82
INCOMPLETE PENETRANCE
Incomplete penetrance has been reported for all the
genes associated with aHUS. Penetrance has been
reported at around 50% for individuals carrying
CFH, CFI, MCP, and CFB mutations,40,90 and slightly
lower for C3 mutations, albeit with small numbers.53 In
index cases, the age-related penetrance is significantly
higher than their mutation-positive relatives regardless
of gene.91 This suggests that the penetrance is altered
by other genetic and environmental modifiers.
Patients have been reported with mutations in more
than one complement gene11,86,92–94 or mutations in
one complement gene in addition to autoantibodies to
complement components.67,78 In a study of 795 aHUS
patients the European Working Party on Complement
Genetics showed that at least 3.4% of aHUS cases will
have more than one mutation. Eight percent to 10% of
patients with mutations in CFH, C3, or CFB had
combined mutations whereas 25% of patients withmutations in CFI or MCP had combined mutations.46
The penetrance increased as the number of mutations
in a patient increased.46 As described, haplotypes and
SNPs act together with mutations and inhibitory auto-
antibodies to increase the penetrance of disease.
Even in the situation in which a patient has multiple
genetic risk factors, disease may not manifest until middle
age, suggesting a triggering stimulus is required for
disease to manifest. In such cases, it is likely that aHUS
results from an otherwise innocuous stimulus that triggers
the AP and sets off a self-amplifying cycle that cannot be
controlled adequately in susceptible individuals.
TRIGGERING EVENTS
Historically, many agents have been linked to aHUS
(Table 1). Although many of these associated con-
ditions are common, aHUS is rare, suggesting an
underlying predisposition.
Recent analysis of cohorts of aHUS patients with
complement mutations have identified upper respiratory
tract infections, fevers, pregnancy, drugs, and non E coli
diarrheal illnesses as potential triggers.40,95–97 Non-Stx
V1658A
H1464D
T1383N
F603V
R735W
S562L
R592Q/W
R1042W/L
K1051M
R425C
A1094V/S
I1095S
I1157T
C1158W
T162R/K
Q185E
R478L
Q1161K
K65Q
R161W
Figure 5. Location of aHUS-associated mutations within the crystal structure of C3 (protein database identification
code: 2A73). The structure of C3 is represented with the domains highlighted: MG1, green; MG2, blue; MG3, violet;
MG4, olive; MG5, pink; MG6, orange; ANA, yellow; α’NT, grey; MG7, lime; CUB, light blue; TED, wheat; MG8,
purple; and C345C, black. Genetic variants (red spheres) cluster around the MG2 and TED domains. Functional
analysis of C3 mutations in aHUS has been performed in only a few cases (Table 6).
D. Kavanagh, T.H. Goodship, and A. Richards518diarrhea preceded aHUS in 23% of a French cohort94 and
in 28% of an Italian cohort.51 Infectious events, mainly
upper respiratory tract infections or diarrhea/gastroenter-
itis, trigger onset of aHUS in at least half of patients.49,51
Likewise, in pregnancy-associated aHUS, Fakhouri et al98
showed that 86% of patients for whom this was a trigger
carried a complement gene mutation. Drugs also may
unmask latent complement defects resulting in aHUS.40,99COMPLEMENT SCREENING IN AHUS
Once the initial diagnosis of a thrombotic microangiop-
athy (TMA) has been made, the initial management
involves differentiating between Stx-HUS, thrombotic
thrombocytopenic purpura, and aHUS (for a diagnostic
algorithm see the article by Loirat and Fremeaux-
Bacchi100). Rapid exclusion by analysis of a disintegrin
and metalloproteinase with a thrombospondin type 1
motif, member 13 (ADAMTS13) activity and micro-
biological analysis for Stx-producing E coli can lead to a
diagnosis of aHUS. After exclusion of Stx-HUS and
thrombotic thrombocytopenic purpura, precipitating
events and the underlying genetic defects predisposing
to aHUS should be sought (Table 8).
Complement analysis in cases of aHUS should
include serum levels of C3, C4, CFH, and CFI beforeplasma exchange. Low C3 levels are seen commonly
in patients with mutations in CFH, CFI, MCP, C3, and
CFB and may point to a complement-mediated proc-
ess, however, normal C3 levels do not exclude the
presence of a mutation in, or autoantibodies against,
the complement system (Table 2).101 Fluorescence-
activated cell sorter analysis of peripheral blood
mononuclear cells provides a quick and relatively
inexpensive screening option for MCP mutations,
although genetic analysis still is required to detect all
changes.
Genetic screening in aHUS is challenging because
most of the disease-associated mutations are individ-
ually rare. In the case of nonsense mutations, large
gene rearrangements, and frame shift mutations, the
functional consequences are certain. In aHUS, mis-
sense mutations or splice-site variations in comple-
ment genes comprise a high proportion of the variants
found and the changes may be of uncertain biologic or
clinical relevance. These VUS pose a challenge when
reporting the genetic results.102 Although predictions
can be made as to the likely significance of a VUS,
ultimately, functional assays are required to assess the
importance of a variant. Such analysis often has led to
the reclassification of a previously described mutation
as an irrelevant polymorphism.30 Care always should
Table 6. Mutations in C3 Reported in aHUS Documenting Functional Analysis
Mutation Domain Expressed
MCP
Binding
CA
Activity
Factor H
Binding
Factor B
Binding
C3 Convertase
Formation Reference
K65Q MG1 Yes N/D N/D ↓ N/D N/D 49,219
R161W MG2 Yes ↓ ↓ 2 * ↑ ↑ 10,49,54
T162R MG2 N/D N/D N/D N/D N/D N/D 51
T162K MG2 N/D N/D N/D N/D N/D N/D 51
Q185E MG2 N/D N/D N/D N/D N/D N/D 51
R425C MG4 N/D N/D N/D N/D N/D N/D 9
R478L MG5 N/D N/D N/D N/D N/D N/D 51
S562L MG6b N/D N/D N/D N/D N/D N/D 9
R592Q MG6b Yes ↓ ↓ 2† 2 N/D 50,53
R592W MG6b Yes ↓ ↓ 2† 2 N/D 50,51
F603V MG6b N/D N/D N/D N/D N/D N/D 11
R735W ANA Yes 2 2 2 2 N/D 50
V762I α’NT N/D N/D N/D N/D N/D N/D 51
Y854X MG7 No N/A N/A N/A N/D N/D 49,50
R1042W TED N/D N/D N/D N/D N/D N/D 51
R1042L TED N/D N/D N/D N/D N/D N/D 11
K1051M TED N/D N/D N/D N/D N/D N/D 51
A1094V TED Yes ↓ ↓ ↓ 2 N/D 50
A1094S TED N/D N/D N/D N/D N/D N/D 49
I1095S TED N/D N/D N/D N/D N/D N/D 49
P1114L TED N/D N/D N/D N/D N/D N/D 49
D1115N TED Yes ↓ ↓ ↓ 2 N/D 50,51
I1157T TED N/D N/D N/D N/D N/D N/D 9,11,51
C1158W TED No N/A N/A N/A N/D N/D 50
Q1161K TED Yes ↓ ↓ ↓ 2 N/D 50
T1383N MG8 N/D N/D N/D N/D N/D N/D 51
H1464D MG8 Yes 2 2 2 2 N/D 49
V1658A C345C Yes N/D N/D 2 ↑ ↑ 52
NOTE. The amino acid numbering refers to the translation start site.
Abbreviations: N/A, not applicable; N/D, not done; MG, macroglobulin domains; TED, thioester-containing domain; α’NT, N-terminal
region of the cleaved α-chain; ANA, anaphylatoxin domain.
*Reported elsewhere to have decreased Factor H binding.219
†Reduced but nonsignificant.
Atypical HUS 519be taken when interpreting these VUS and screening
laboratories should revisit past genetic data in light of
new evidence. In addition to direct DNA sequencing,
the not-insubstantial number of gene conversionsTable 7. CFH-Autoantibody Associated aHUS
Dragon-Durey
et al65
Noris
et al51
M
et
Percentage aHUS 749 4
Relapse 59% 37.5% 2
Children 84% 75% 1
Adult 16% 25%
Low C3 levels 58% 43% 2
Long-term follow-up
evaluation
ESRF 27% 63% 4
Death 9.5% 0%
Death/ESRF 36.5% 63% 4
Abbreviations: ESRF, end-stage renal failure; N/A, not applicable.and genomic rearrangements found in aHUS makes
copy number analysis essential in aHUS screening
(see www.genetests.org for national screening
laboratories).oore
al67
Abarrategui-Garrido
et al64
Jozsi
et al66
Geerdink
et al10
9 4.6 11 13
3% N/A N/A 60%
00% 100% 100% 100%
0% 0% 0% 0%
3%
6% 28.5% N/A 0%
0% 14% N/A 16.6%
6% 42.5% N/A 16.6%
Table 8. Evaluation of Thrombotic Microangiopathies
Hematologic Thrombocytopenia
Microangiopathic hemolytic anemia (typically Coombs-negative)
Biochemical Increased lactate dehydrogenase
Increased creatinine
Urinary Proteinuria
Hematuria
Shiga-toxin E. Coli infection Stool/rectal swab culture
Polymerase chain reaction STX
Anti-lipopolysaccharide antibodies
Thrombotic thrombocytopenic purpura ADAMTS13 activity
Complement analysis C3, C4
CFH, CFI, C3Nef
MCP fluorescence-activated cell sorter analysis
Anti–factor H and I autoantibodies
Genetic analysis CFH, CFI, CFB, C3 MCP (including copy number variation)
S pneumoniae Culture
Positive T-antigen
Pregnancy Pregnancy test
Virology Human immunodeficiency virus serology
H1N1 serology
Cytomegalovirus polymerase chain reaction
Epstein-Barr virus polymerase chain reaction
Autoimmune diseases ANA
Anti–double-stranded DNA
Antiphospholipid Ab
Metabolic Plasma amino acid chromatography
Urine organic acid chromatography
Genetic analysis
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The overall prognosis for patients with aHUS has been
poor. Initial mortality has been reported to be higher in
children (6.7% versus 0.8% at 1 year),49 although
adults progress to end-stage renal disease (ESRD)
more frequently at initial presentation (46% versus
16%).49 At 3 to 5 years after onset, 36% to 48%49,51 of
children and 64% to 67%49,51 of adults had died or
reached ESRD.
Prognosis varies with genotype, with MCP muta-
tions carrying the best prognosis,49,51,94 although in
one study this was true only if the first presentation of
aHUS occurred in childhood49 (Table 2). No patient
with an MCP mutation from either the French49 or
Italian cohorts51 died at first episode and none of the
children and only 25% of adults with anMCP mutation
developed ESRD at first episode. At 3 years only 6%
of all patients with MCP mutations51 had developed
ESRD and by 5 years only 35% had developed
ESRD.49
Individuals with mutations in CFH, CFI, or C3 all
had poor outcomes. In patients with a CFH mutation
the initial mortality rate was 30% in children and 4% in
adults,49 and evolution to ESRD at first episode in
survivors was 19% to 33% in children and 48% inadults.49,51 At 3 to 5 years of follow-up evaluation, up
to 77% of patients with CFH mutations had developed
ESRD or had died. Only 30% to 40% of individuals
with CFI and C3 mutations will be alive with native
kidney function at 3 to 5 years.49,51 The prognosis of
aHUS with CFB mutations also is poor.51,55,56
A proportion of patients will have combined muta-
tions. In patients with either CFH or CFI mutations,
the presence of mutations in other genes did not
modify prognosis. In contrast, the prognosis for indi-
viduals with an MCP mutation was worse if they also
carried an additional mutation.46
In those patients with CFH autoantibodies, 36.5% to
63% die or reach ESRD in the long term49,51,64–67
(Table 7).EXTRARENAL MANIFESTATIONS
Extrarenal manifestations are reported in only 10% to
20% of patients with aHUS. The most frequently
reported symptoms (10%) are neurologic, with
symptoms ranging from irritability to coma. It is
unclear how many of these symptoms are the direct
result of a cerebral TMA, with severe hypertension and
posterior reversible encephalopathy syndrome possible
Table 9. Extrarenal Manifestations Associated With aHUS
Extrarenal manifestation Reference
Digital gangrene 220–222
Cerebral artery thrombosis/stenosis 222–224
Extracerebral artery stenosis 223
Cardiac involvement/myocardial infarction 51,225
Ocular involvement 226
Pulmonary involvement 51,94
Pancreatic involvement 51
Atypical HUS 521differential diagnoses that may be differentiated on
magnetic resonance imaging.103 Many case reports of
other organ involvement occurring concurrently with
aHUS have been described (Table 9), but in the
majority, definitive biopsy evidence of TMA in the
organ was lacking. Extrarenal manifestations have
been reported more commonly in CFH-autoantibody–
mediated disease, with 23.5% having seizures and
23.1% developing pancreatitis.65Neurologic involvement 51,94,103TREATMENT
Plasma Exchange
Until the beginning of this decade, plasma exchange
(PE) was considered the gold standard for management
of aHUS. The replacement of nonfunctioning comple-
ment proteins and removal of CFH autoantibodies and
hyperfunctional complement components (eg, gain-of-
function mutations) made PE a logical choice
(reviewed in European104 and UK105 guidelines on
aHUS treatment). The consensus-based guidelines
recommended that PE should be commenced as soon
as possible after diagnosis of aHUS, using 1 to
2 plasma volumes per session in adults and 50 to
100 mL/kg in children. Initially, PE should be per-
formed daily and the dose titrated to control hemolysis.
Once hemolysis has been controlled, PE can be with-
drawn slowly, although individuals with genetic
defects in the complement system are frequently
plasma dependent and require long-term plasma ther-
apy (weekly/biweekly) to maintain remission. Only
once ADAMTS13 deficiency is excluded should ecu-
lizumab be considered. The price of eculizumab will
mean that PE will remain the only currently available
option in many countries.Eculizumab
Eculizumab, a recombinant humanized monoclonal
antibody directed against C5, blocks the cleavage of
C5 into its effector components C5a and C5b.106 Since
the initial use of this complement inhibitor in aHUS in
2009,107 the effectiveness of eculizumab has been
communicated in many case reports107–119, meeting
abstracts120–125, and a recently published prospective
trial.125a
Eculizumab appears highly effective, with approx-
imately 85% of patients becoming disease-free in both
plasma-resistant and plasma-dependent aHUS (revie-
wed by Wong et al126). It is effective in patients with
and without identified complement mutations. Similar
to PE, the earlier eculizumab is commenced, the
greater the preservation of kidney function. It has been
suggested that eculizumab achieves better control of
disease as witnessed by improvement in renal functionafter switching from PE and in rescuing plasma-
resistant individuals.126 It should be noted, however,
that a randomized trial of eculizumab against PE was
not, and is unlikely to be, performed.
Treatment with eculizumab should begin as soon as
Stx-HUS and ADAMTS13 deficiency can be elimi-
nated. Current protocols suggest life-long treatment
with eculizumab will be required, however, as we gain
more clinical experience it is likely that there will be
certain subgroups in whom the treatment can be
stopped (eg, those with isolated MCP mutations).
Eculizumab has been used safely during pregnancy in
patients with paroxysmal nocturnal hemoglobinuria.126
Because host defense against encapsulated organ-
isms is dependent on the ability to form a membrane
attack complex (C5b-9), vaccination against Neisseria
meningitides is required before treatment with eculizu-
mab. However, because the current vaccine (tetrava-
lent) does not cover the most prevalent strain
(serogroup B), long-term prophylactic antibiotic cover
also has been suggested.126RENAL TRANSPLANTATION IN aHUS
The outcome of renal transplantation in patients with
aHUS is poor. In one adult series of 71 renal trans-
plants, the 5-year death-censored graft survival was
only 51%, with a 7% mortality rate at 5 years.99 Graft
failure is predominantly due to aHUS recurrence which
occurs in 60% to 70% of patients,99,127 and occurs
early after transplant (70% in the first year after
transplant99).
The outcome of renal transplantation is predicted
largely by the underlying genetic abnormality. In
individuals with mutations in CFH the recurrence rate
is greater than 80%. Similarly, activating mutations in
C3 and CFB also have a high risk of renal recurrence.
Initial studies all suggested that mutations in CFI
carried a poor prognosis, although more recently
one study failed to replicate these data.99 It is likely
that this variation in data reflects the functional
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Unlike the complement proteins described earlier,
MCP is membrane-tethered and is not a plasma
protein. As such, a renal allograft will correct the
complement defect and protect against aHUS. In
keeping with this, the outcome after transplantation
in those with mutations in MCP is much better, with a
recurrence rate of only approximately 20%.128 It has
been suggested that in those who do recur, an addi-
tional genetic predisposition such as an at-risk haplo-
type may be present47 or endothelial microchimerism
may occur.129 In keeping with this, outcomes were
worse in individuals with combined MCP mutations
compared with patients with an isolated MCP
change.46 Only one individual with a loss-of-function
mutation in THBD has undergone transplantation to
date and they had recurrent disease.60
It is perhaps not surprising that individuals with
underlying genetic defects have a high recurrence rate
because the post-transplant milieu provides the neces-
sary disease triggers (eg, viral diseases, ischemia
reperfusion injury, donor-specific antibodies, immuno-
suppressive drugs, and so forth) to cause endothelial
cell damage and activation of the complement cascade.
Calcineurin inhibitors (tacrolimus and cyclosporin),
although consistently linked as a trigger for aHUS,
were not shown to be associated significantly in two
recent studies of aHUS recurrence post-transplant.99,127
Mammalian target of rapamycin inhibitors (eg, siroli-
mus), however, have been reported to increase the risk
of recurrence.99
Although plasma therapy has a low success rate in
rescuing recurrent aHUS after renal transplantation,
pre-emptive plasma exchange has been associated with
a trend to decrease recurrence.99 Such a regimen may
now be superseded by pre-emptive eculizumab.
AUTOANTIBODIES
There is limited information regarding the outcome
after transplantation in individuals with CFH autoanti-
bodies. Two patients have been reported to have
CFH autoantibodies and recurrent aHUS.130,131 Two
individuals had successful renal transplants using
pre-emptive removal of CFH autoantibodies using
rituximab and PE.131,132 Five individuals with factor
H autoantibodies have successfully undergone renal
transplantation in the absence of specific therapy aimed
at reducing CFH autoantibody titers with follow-up
evaluation ranging from 2 to 17 years with no
recurrence.64,67 An additional confounding factor is
that CFH autoantibodies frequently are found in
association with other mutations. A pragmatic
approach would be to use a regimen designed to
remove CFH autoantibodies in those with a high titer.LIVING RELATED TRANSPLANTATION
Live related transplantation is a particularly unattrac-
tive option in aHUS given the high recurrence rate and
graft loss in the recipient. In addition, de novo aHUS
has been recorded in four donors within a year of
donation.31,133–135 In at least one of these cases, a CFH
mutation in the donor subsequently was reported.31
Although genotyping may reveal a known mutation in
a family member, the additional presence of risk
haplotypes and the fact that further genetic risk factors
remain to be discovered makes it impossible to rule out
subsequent aHUS for a donor.LIVER/KIDNEY TRANSPLANTATION
Because CFH, CFI C3, and CFB are synthesized
predominantly in the liver; combined liver/kidney
transplantation has been viewed as a mechanism to
correct the underlying genetic deficiency of comple-
ment regulation. Twenty liver/kidney transplants have
been reported in the literature to date.100,127,136–145 The
initial attempts were not successful because they did
not include preoperative PE to correct the underlying
complement defects.136,137 In this setting, ischemia-
reperfusion injury triggered the complement cascade,
resulting in primary liver nonfunction.
Subsequently, Saland et al144 introduced perioper-
ative PE in addition to aspirin and heparin, which has
resulted in improved outcomes. Treatment guidelines
for the use of liver-kidney transplantation in aHUS
were recently proposed by a consensus conference.146
Despite this, of the 14 patients who underwent the
revised procedure, 2 died (14% surgical mortality), and
the availability of eculizumab may change the risk-
benefit profile of this type of surgery.DE NOVO aHUS AFTER RENAL TRANSPLANT
The role of genetic defects in the complement system
has also been shown in de novo aHUS after renal
transplant. In a series of transplant patients whose
initial diagnosis was not aHUS, 29% were seen to have
a mutation in CFI or CFH.147 This may be an under-
representation of the genetic predisposition because the
genes for CFB and C3 were not screened. The majority
of these patients had chronic glomerulonephritis or
malignant hypertension as their initial diagnosis.
Mesangiocapillary glomerulonephritis/C3 glomerulop-
athy share many of the same complement risk factors
as aHUS and the transformation from mesangiocapil-
lary glomerulonephritis to aHUS is well recognized.
Likewise, a patient presenting at ESRD with a biopsy
picture of malignant hypertension is indistinguishable
from aHUS. We would recommend that such patients
Atypical HUS 523also should be screened for complement mutations
before transplantation.
More recently, a liver transplant recipient was shown
to have developed de novo aHUS. Genetic analysis
showed that the recipient carried a risk MCP haplotype
but did not have a mutation. DNA from the donor liver,
however, was shown to carry a mutant CFH. This is
further evidence of the role of susceptibility genes in
predisposing to post-transplant aHUS.148ECULIZUMAB USE IN RENAL TRANSPLANTATION
Eculizumab has also been used successfully in renal
transplantation in those experiencing recurrent aHUS
in a transplant149–154 and as prophylaxis before trans-
plantation in those with a known mutation.155–158 In a
recent review, Zuber et al159 reported that of 9 patients
with complement mutations, 8 had successful renal
transplants under eculizumab prophylaxis and 13
patients had successful salvage treatment for recurrent
aHUS after transplant. In those individuals with
ESRD secondary to complement-mediated aHUS
requiring renal transplantation, it is probable that
prophylactic eculizumab will become the treatment
of choice.SUMMARY
Overactivity of the AP is central to the pathogenesis of
aHUS. Many underlying genetic complement predis-
positions have been described but disease only mani-
fests after an environmental trigger. The understanding
of the role of complement in the pathogenesis of aHUS
has facilitated the introduction of a successful treat-
ment in the form of the complement C5 inhibitor,
eculizumab.
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